Follow RSS for latest reports on this topicGilotrif (Afatinib) - Market Research and Reports
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Manufacturer: Boehringer Ingelheim
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
We found 1 reports that matched your search.
Refine your search, and find more matches, using the form above.
Global and Chinese Afatinib dimaleate Industry, 2017 Market Research Report [Report Updated: 07-04-2017]
The 'Global and Chinese Afatinib dimaleate Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Afatinib dimaleate industry with a focus on the Chinese market. The report provides key statistics on the market status of the Afatinib dimaleate manufacturers and is a valuable source of guidance and direction for companies and individuals ...Read More >>>
Published by: Prof Research
Prices Starting From: